JP2006503009A5 - - Google Patents

Download PDF

Info

Publication number
JP2006503009A5
JP2006503009A5 JP2004527872A JP2004527872A JP2006503009A5 JP 2006503009 A5 JP2006503009 A5 JP 2006503009A5 JP 2004527872 A JP2004527872 A JP 2004527872A JP 2004527872 A JP2004527872 A JP 2004527872A JP 2006503009 A5 JP2006503009 A5 JP 2006503009A5
Authority
JP
Japan
Prior art keywords
triazol
phenyl
methyl
chloro
ylsulfanylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004527872A
Other languages
English (en)
Japanese (ja)
Other versions
JP4637578B2 (ja
JP2006503009A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/024846 external-priority patent/WO2004014881A2/en
Publication of JP2006503009A publication Critical patent/JP2006503009A/ja
Publication of JP2006503009A5 publication Critical patent/JP2006503009A5/ja
Application granted granted Critical
Publication of JP4637578B2 publication Critical patent/JP4637578B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004527872A 2002-08-09 2003-08-08 代謝調節型グルタミン酸受容体−5の調節因子としての1,2,4−オキサジアゾール類 Expired - Fee Related JP4637578B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40204002P 2002-08-09 2002-08-09
PCT/US2003/024846 WO2004014881A2 (en) 2002-08-09 2003-08-08 '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010135508A Division JP2010248214A (ja) 2002-08-09 2010-06-14 代謝調節型グルタミン酸受容体−5の調節因子としての1,2,4−オキサジアゾール類

Publications (3)

Publication Number Publication Date
JP2006503009A JP2006503009A (ja) 2006-01-26
JP2006503009A5 true JP2006503009A5 (enExample) 2006-12-07
JP4637578B2 JP4637578B2 (ja) 2011-02-23

Family

ID=31715777

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004527872A Expired - Fee Related JP4637578B2 (ja) 2002-08-09 2003-08-08 代謝調節型グルタミン酸受容体−5の調節因子としての1,2,4−オキサジアゾール類
JP2010135508A Pending JP2010248214A (ja) 2002-08-09 2010-06-14 代謝調節型グルタミン酸受容体−5の調節因子としての1,2,4−オキサジアゾール類

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010135508A Pending JP2010248214A (ja) 2002-08-09 2010-06-14 代謝調節型グルタミン酸受容体−5の調節因子としての1,2,4−オキサジアゾール類

Country Status (20)

Country Link
US (2) US20040152699A1 (enExample)
EP (1) EP1529045A2 (enExample)
JP (2) JP4637578B2 (enExample)
KR (1) KR20050033070A (enExample)
CN (2) CN1894241A (enExample)
AR (1) AR040847A1 (enExample)
AU (1) AU2003259068B2 (enExample)
BR (1) BR0313265A (enExample)
CA (1) CA2494987C (enExample)
IL (1) IL166510A0 (enExample)
IS (1) IS7733A (enExample)
MX (1) MXPA05001594A (enExample)
NO (1) NO20051225L (enExample)
NZ (1) NZ538225A (enExample)
PL (1) PL375256A1 (enExample)
RU (1) RU2352568C9 (enExample)
TW (1) TWI341314B (enExample)
UA (1) UA87653C2 (enExample)
WO (1) WO2004014881A2 (enExample)
ZA (1) ZA200500886B (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL375256A1 (en) * 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
SI1644363T1 (sl) 2003-05-30 2012-07-31 Gemin X Pharmaceuticals Canada Inc Triheterociklične spojine sestavki in postopki za zdravljenje raka
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
RU2006127575A (ru) * 2004-02-18 2008-03-27 Астразенека Аб (Se) Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
TW200538108A (en) 2004-02-19 2005-12-01 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
CA2557115C (en) * 2004-02-23 2012-10-02 Glaxo Group Limited Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
JP2007530589A (ja) * 2004-03-26 2007-11-01 アンフォラ ディスカバリー コーポレーション 特定のトリアゾールを基礎とする化合物、組成物、およびそれらの使用
CA2580409C (en) 2004-09-16 2013-08-13 Astellas Pharma Inc. Triazole derivative or salt thereof
JP4557685B2 (ja) 2004-11-15 2010-10-06 独立行政法人理化学研究所 蛍光蛋白質
EP1817030A2 (en) * 2004-12-01 2007-08-15 Kalypsys, Inc. Inducible nitric oxide synthase dimerization inhibitors
AU2006205920B2 (en) * 2005-01-14 2012-11-15 F. Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mGluR5 antagonists
WO2006080533A1 (ja) * 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. 3-アミノ-1,2,4-トリアゾール誘導体
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
UY29796A1 (es) * 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
EP1954694A1 (en) * 2005-11-28 2008-08-13 Kalypsys, Inc. Imidazole derivatives as nitric oxide synthase dimerisation inhibitor
TW200811157A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
TW200821305A (en) * 2006-10-05 2008-05-16 Astrazeneca Ab MGluR5 modulators
NZ577111A (en) * 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
EP1958631A1 (en) * 2007-02-14 2008-08-20 AEterna Zentaris GmbH Novel triazole derivatives as ligands of G-protein coupled receptors
EA201070143A1 (ru) 2007-07-13 2010-08-30 Аддекс Фарма С.А. Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
BR122018001845B1 (pt) 2007-08-13 2019-11-26 Monsanto Technology Llc compostos para controlar nematódeos, composições compreendendo os mesmos e método de controle de nematódeos
WO2009051705A1 (en) * 2007-10-18 2009-04-23 Merck & Co., Inc. Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
KR20100090777A (ko) 2007-10-19 2010-08-17 아스트라제네카 아베 대사성 글루타메이트 수용체 (mglur)의 조절제로서의 테트라졸 유도체
WO2009054785A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole ether derivatives as modulators of mglur5
MX2010011870A (es) * 2008-04-28 2010-12-20 Astrazeneca Ab Metodos de preparacion de heterociclos sustituidos.
ES2383246T3 (es) 2008-06-05 2012-06-19 Glaxo Group Limited 4-amino-indazoles
ES2526966T3 (es) 2008-06-05 2015-01-19 Glaxo Group Limited Compuestos novedosos
ES2445199T3 (es) 2008-06-05 2014-02-28 Glaxo Group Limited Derivados de benzpirazol como inhibidores de PI3-quinasas
US8716317B2 (en) 2008-06-09 2014-05-06 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US8703809B2 (en) 2008-06-30 2014-04-22 Novartis Ag Combination products
MX2011000179A (es) 2008-07-03 2011-04-05 Astellas Pharma Inc Derivado de triazol o su sal.
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
MX2011005982A (es) * 2008-12-18 2011-06-27 Astrazeneca Ab Nuevo proceso para preparar 1-[5-(3-clorofenil)isoxazol-3-il]etano na y (r)-1-[5-(3-clorofenil)isoxazol-3-il]etanol.
ES2542551T3 (es) 2009-03-09 2015-08-06 Glaxo Group Limited 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
AU2010243613B2 (en) 2009-04-30 2015-05-07 Glaxo Group Limited Oxazole substituted indazoles as PI3-kinase inhibitors
US8883827B2 (en) 2009-06-05 2014-11-11 Oslo University Hospital Hf Azole derivatives as WTN pathway inhibitors
US20110144049A1 (en) * 2009-10-21 2011-06-16 Serebruany Victor L Treating Cardiac Arrhythmias, Heart Failure, Peripheral Artery Disease and Stroke with Cyclopentyl-Triazolo-Pyrimidine or Derivative Thereof
TWI481607B (zh) * 2009-12-17 2015-04-21 Lundbeck & Co As H 作為pde10a酵素抑制劑的2-芳基咪唑衍生物
CA2784768C (en) * 2009-12-29 2015-02-03 Eli Lilly And Company Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia
WO2011107530A2 (en) * 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
MX2012012615A (es) 2010-04-30 2012-12-17 Novartis Ag Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs).
WO2012006760A1 (en) * 2010-07-14 2012-01-19 Merck Sharp & Dohme Corp. Tricyclic compounds as allosteric modulators of metabotropic glutamate receptors
UA112418C2 (uk) 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
WO2012058128A2 (en) * 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Caprolactam mglur5 receptor modulators
JP2013544874A (ja) 2010-12-08 2013-12-19 オスロ ユニヴァーシティー ホスピタル エイチエフ Wntシグナル伝達経路阻害薬としてのトリアゾール誘導体
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
WO2012151136A1 (en) * 2011-05-03 2012-11-08 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
US8592423B2 (en) 2011-06-21 2013-11-26 Bristol-Myers Squibb Company Inhibitors of PDE10
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013131981A1 (en) 2012-03-08 2013-09-12 Novartis Ag Predictive markers useful in the diagnosis and treatment of fragile x syndrome (fxs)
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
HK1215256A1 (zh) 2012-11-20 2016-08-19 Vertex Pharmaceuticals Incorporated 用作吲哚胺2,3-二氧化酶的抑制劑的化合物
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
MX383686B (es) 2013-07-31 2025-03-14 Novartis Ag Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
EP3233842B1 (en) 2014-12-17 2025-03-26 King's College London Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
EP3159332A1 (en) 2015-10-23 2017-04-26 Ludwig-Maximilians-Universität München 5,5'-bis(2,4,6-trinitrophenyl)-2,2'-bi(1,3,4-oxadiazole) and bis(2,4,6-trinitrobenzoyl)oxalohydrazide
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
WO2017218337A1 (en) 2016-06-13 2017-12-21 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation
SI3600309T1 (sl) 2017-03-28 2022-10-28 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
SG11202002322TA (en) * 2017-09-14 2020-04-29 Daiichi Sankyo Co Ltd Compound having cyclic structure
KR102349776B1 (ko) 2017-11-17 2022-01-10 셀릭스 바이오 프라이빗 리미티드 눈 질환의 치료를 위한 조성물 및 방법
AU2019384074B2 (en) 2018-11-20 2025-04-10 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids
WO2020150136A1 (en) 2019-01-15 2020-07-23 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
US11524005B2 (en) 2019-02-19 2022-12-13 Gilead Sciences, Inc. Solid forms of FXR agonists
EP3771711A1 (en) 2019-07-29 2021-02-03 Bayer Animal Health GmbH Pyrazole derivatives for controlling arthropods
CN111362934A (zh) * 2020-04-21 2020-07-03 南开大学 一类异噻唑联噁二唑衍生物及其制备方法和用途
CA3250533A1 (en) 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR TREATING EXCESS GLUCOCORTICOIDS
CR20240536A (es) 2022-05-19 2025-01-29 Astrazeneca Ab Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas
CN115716822B (zh) * 2022-11-14 2025-05-16 徐州医科大学 苯并咪唑基异噁唑类化合物在制备与多发性骨髓瘤有关药物方面的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740434A (en) * 1966-12-23 1973-06-19 American Cyanamid Co Substituted nitroimidazolylthiadiazoles and oxadiazoles as antiprotozoal agents
US3816426A (en) * 1970-10-27 1974-06-11 Abbott Lab 1-(5-phenyl-4-oxo-2-oxazolin-2-yl)piperazines
JPS56127364A (en) 1980-03-01 1981-10-06 Mitsui Toatsu Chem Inc Novel piperazine compound, its preparation and utilization
JP3003148B2 (ja) 1989-01-05 2000-01-24 藤沢薬品工業株式会社 チアゾール化合物、その製造法およびそれを含有する医薬組成物
US5140034A (en) * 1989-03-14 1992-08-18 Merck Sharp & Dohme Ltd. Five-membered ring systems with bonded imidazolyl ring substituents
US4914207A (en) * 1989-05-09 1990-04-03 Pfizer Inc. Arylthiazolylimidazoles
DE3929673A1 (de) * 1989-09-07 1991-03-14 Bayer Ag Substituierte carbamoyltriazole
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
CA2146019A1 (en) * 1992-10-23 1994-05-11 Howard B. Broughton Dopamine receptor subtype ligands
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
DE19725450A1 (de) 1997-06-16 1998-12-17 Hoechst Schering Agrevo Gmbh 4-Haloalkyl-3-heterocyclylpyridine und 4-Haloalkyl-5-heterocyclylpyrimidine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
DE19858193A1 (de) * 1998-12-17 2000-06-21 Aventis Cropscience Gmbh 4-Trifluormethyl-3-oxadiazolylpyridine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
CN1158264C (zh) * 1997-11-21 2004-07-21 Nps药物有限公司 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂
DE19858192A1 (de) * 1998-12-17 2000-06-21 Aventis Cropscience Gmbh 4-Trifluormethyl-3-oxazolylpyridine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
DE19858191A1 (de) 1998-12-17 2000-06-21 Aventis Cropscience Gmbh 4-Haloalkyl-3-heterocyclylpyridine und 4-Haloalkyl-5-heterocyclyl-pyrimidine und ihre Verwendung als Repellentien
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
HUP0202757A3 (en) 1999-08-19 2006-03-28 Nps Pharmaceuticals Inc Salt L Heteropolycyclic compounds, pharmaceutical compositions containing them and their use as metabotropic glutamate receptor antagonists
JP2003510359A (ja) * 1999-10-01 2003-03-18 スミスクライン・ビーチャム・コーポレイション 化合物および方法
TWI283577B (en) 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
DE19962901A1 (de) 1999-12-23 2001-07-05 Aventis Cropscience Gmbh Azolylalkalylazol-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
EP1318992B1 (en) 2000-09-21 2005-07-27 Smithkline Beecham Plc Imidazole derivatives as raf kinase inhibitors
IL155999A0 (en) 2000-12-04 2003-12-23 Hoffmann La Roche Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
ATE292633T1 (de) 2001-07-19 2005-04-15 Cv Therapeutics Inc Substituierte piperazinderivate und ihre verwendung als fettsaüreoxidationsinhibitoren
PL375256A1 (en) * 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
SI1716152T1 (sl) 2004-02-18 2008-12-31 Astrazeneca Ab Kondenzirane heterociklične spojine in njihova uporaba kot antagonisti metabotropnega receptorja za zdravljenje gastrointestinalnih motenj
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
UY29796A1 (es) * 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor

Similar Documents

Publication Publication Date Title
JP2006503009A5 (enExample)
WO2004014881B1 (en) '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
JP2006506340A5 (enExample)
JP2006502134A5 (enExample)
RU2009111113A (ru) Мидуляторы mglur5
WO2005077345A1 (en) Compounds for the treatment of gastro-esophageal reflux disease
JP2007523182A5 (enExample)
RU2018143324A (ru) Применение 1H-пиразоло[4,3-b]пиридинов в качестве ингибиторов PDE1
JP2007523208A5 (enExample)
JP2010533158A5 (enExample)
RU2006127575A (ru) Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
IL303196A (en) Heteroaryl-substituted pyridines and methods of use
JP2015517580A5 (enExample)
JP2014523400A5 (enExample)
CA2557115A1 (en) Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
JP2019516737A5 (enExample)
JP2011503166A5 (enExample)
JP2013518046A5 (enExample)
HRP20230789T1 (hr) Derivati benzhidroksamske kiseline kao selektivni inhibitori hdac6
JP2006513258A5 (enExample)
RU2008126398A (ru) Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpti)
JP2008546836A (ja) 新規な用途
JP2007523181A5 (enExample)
JP2017502049A5 (enExample)
RU2011103789A (ru) Производное триазола или его соль